Navigation Links
Sulonex in Medical News

Keryx Biopharmaceuticals Settles License Dispute With Alfa Wassermann

...ERX ) announced today that the Company and Alfa Wassermann S.p.A. have settled a dispute over issues arising from the terminated license agreement for sulonex (sulodexide). Under the terms of the settlement agreement, Alfa Wassermann is paying Keryx US$3,500,000 (of which US$2,750,000 has already been receiv...

Keryx Biopharmaceuticals, Inc. Announces First Quarter 2009 Financial Results

...income (loss) was primarily attributable to a $25,894,000 decrease in research and development expenses related to the cessation of the development of sulonex in March 2008, a $2,671,000 and $344,000 decrease in research and development expenses related to KRX-0401 and Zerenex, respectively, a $3,128,000 inc...

Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2008 Financial Results

...e in net loss was primarily attributable to a $11,699,000 decrease in research and development expenses related to the cessation of the development of sulonex in March 2008, a $1,860,000 decrease in expenses related to our other clinical compounds, and a $519,000 decrease in non-cash compensation expense rel...

Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results

...e in net loss was primarily attributable to a $10,390,000 decrease in research and development expenses related to the cessation of the development of sulonex in March 2008, an $852,000 decrease in expenses related to our other clinical compounds, a $567,000 decrease in non-cash compensation expense related ...
Sulonex in Medical Technology

Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial

...sed on a review of the available proteinuria data, sulonex did not appear to be different than placebo. The s...here can be no assurance that the results from the sulonex Phase 3 and/or Phase 4 study will track the data f...he DiNAS Phase 2 study. Results from these earlier sulonex studies may not be indicative of results from futu...

Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint

...sults from its SUN-MICRO Phase 3 clinical trial of sulonex (sulodexide) for the treatment of diabetic nephrop...here can be no assurance that the results from the sulonex Phase 3 study will track the data from the pilot C...he DiNAS Phase 2 study. Results from these earlier sulonex studies may not be indicative of results from futu...

Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial

...A filing before year end. "The completion of the sulonex Phase 3 clinical program is an important and signi...d analyzing the data from this study." ABOUT THE sulonex (sulodexide oral gelcap) PHASE 3 and PHASE 4 CLINI...e of the filing of the NDA for sulodexide. ABOUT sulonex (sulodexide oral gelcap) Sulodexide belongs to a...

Sulodexide Data Safety Monitoring Committee Completes Additional Review of Phase 3 Study Data

...rial. The DSMC raised no safety concerns regarding sulonex or the trial. As planned, no review was conducted ...SULONEX(TM) PHASE 3 and PHASE 4 CLINICAL PROGRAM sulonex is in a pivotal Phase 3 and Phase 4 clinical progr...ling of the NDA for Sulonex. ABOUT SULONEX(TM) sulonex (sulodexide oral gelcap) belongs to a proposed new...

Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois

...rael, New York, NY ABOUT SULONEX(TM) sulonex (sulodexide oral gelcap) belongs to a proposed new...es in which the kidneys are progressively damaged. sulonex is a glycosaminoglycan compound with structural si...n excretion in patients with diabetic nephropathy. sulonex is in a pivotal Phase III and Phase IV clinical pr...

Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstrom's Macroglobulinemia

...s KRX-101, a first-in-class, oral heparinoid compound for the treatment of diabetic nephropathy, a life-threatening kidney disease caused by diabetes. sulonex is in a pivotal Phase III and Phase IV clinical program under a Special Protocol Assessment with the Food & Drug Administration. Additionally, Ker...
Sulonex in Biological Technology

Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results

...cash from a settlement with the former licensor of sulonex (sulodexide). The Company will receive an additio...ses related to the cessation of the development of sulonex in March 2008. The net income for the six m...ses related to the cessation of the development of sulonex in March 2008, a $4.4 million decrease in research...

Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results

...rch and development expenses related to the cessation of the development of sulonex in March 2008, a $7,013,000 and $2,735,000 decrease in research and develop...rch and development expenses related to the cessation of the development of sulonex in March 2008, a $8,165,000 and $1,401,000 decrease in research and develop...

Keryx Biopharmaceuticals, Inc. Announces First Quarter 2008 Financial Results

... cessation of our development of Sulonex. Such costs included an $11,037,000 non-cash impairment charge related to the write-down of the assets of the sulonex manufacturing suite to their estimated fair value, and a $2,063,000 provision for estimated costs relating to the required restoration of the manufact...

Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan

...17 million, and is primarily related to the completion and shut-down of the sulonex clinical program and restructuring costs. Additional elements of the Comp... severance benefits and a non-cash write-off of the assets of the Company's sulonex manufacturing facility. As part of the workforce reduction, the position ...

Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint

...sults from its SUN-MICRO Phase 3 clinical trial of sulonex (sulodexide) for the treatment of diabetic nephrop...here can be no assurance that the results from the sulonex Phase 3 study will track the data from the pilot C...he DiNAS Phase 2 study. Results from these earlier sulonex studies may not be indicative of results from futu...

Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results

... and development expenses related to the Company's sulonex pivotal Phase 3 and Phase 4 clinical program, a $6...iew of the safety and efficacy data related to the sulonex Phase 3 trial, at which time the DSMC again found ...r ability to finalize the new drug application for sulonex before year-end, even if we receive positive resul...

Keryx Biopharmaceuticals Announces Additions to Management Team

...o build the corporate infrastructure to manage both the potential launch of sulonex and the future development and commercialization of our other drug candidat...o differ materially are the following: the results of the Phase 3 study for sulonex could be inconclusive or negative; even if we receive positive results from...

Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results

...,000 increase in research and development expenses related to the Company's sulonex pivotal Phase III and Phase IV clinical program, a $3,834,000 increase in e...lue of our product portfolio. We continue to stay focused on completing the sulonex clinical development program, with data from our Phase III study expected i...
Other Tags
(Date:7/30/2014)... Vail and Beaver Creek, Colo., skiers ... with “Blind Skier.” Those skiers and guides are enjoying ... Guides , a non-profit organization founded in 2001 that ... (VIPs) for snow sport opportunities. Visually impaired skiers and ... and pick up an application to participate in the ...
(Date:7/30/2014)... Push to Walk and Macy’s invite ... For A Cause” charity shopping event on August 23, ... one-day-only shopping event created to support local charities’ fundraising ... for charities across the country since 2006. Customers can ... from Push to Walk now. , “Macy’s ...
(Date:7/30/2014)... Calling all runners in the Richmond, VA region. ... host a monthly Runner’s Injury Clinic at the ... the second Monday of each month through the end of ... 10 and December 8. , The clinics run from ... running shoes and attire, will receive a complimentary evaluation of ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 The ... with the Penn's Abramson Cancer Center, will host a ... together area experts in the field of mesothelioma. September ... The conference is open to the public, and specifically ... and those who have been exposed to asbestos. , ...
(Date:7/30/2014)... Ohio (PRWEB) July 31, 2014 CareSource, ... Douglas A. Fecher President and CEO, Wright-Patt Credit Union, ... Fecher, is a foremost financial CEO with an extensive ... president of lending and later chief operating officer at ... Fecher has led the Beavercreek-based Wright-Patt Credit Union that ...
Breaking Medicine News(10 mins):Health News:Colorado Non-Profit Foresight Ski Guides Seeking Applications for Blind and Visually Impaired Skiers and Guides for Vail Ski Season 2Health News:Push to Walk Participates in Macy’s Ninth Annual “Shop For A Cause” 2Health News:Push to Walk Participates in Macy’s Ninth Annual “Shop For A Cause” 3Health News:Tidewater Physical Therapy to Host Monthly Runner’s Injury Clinic at 3 Sports Glen Allen Location 2Health News:Tidewater Physical Therapy to Host Monthly Runner’s Injury Clinic at 3 Sports Glen Allen Location 3Health News:September Events: Regional Conference on Mesothelioma in Philadelphia 2Health News:September Events: Regional Conference on Mesothelioma in Philadelphia 3
(Date:7/30/2014)... University is paving the way for a breakthrough ... military troops exposed to poisonous chemicalsparticularly those in ... in the current issue of the journal ... which are compounds commonly used in pesticides and ... NYU School of Engineering Associate Professor of Chemical ...
(Date:7/30/2014)... uses reversible epigenetic processes to regulate its genes, and ... a picture of the genome regulation taking place in ... Genome Biology and illustrates how the truffle ... genes,. The authors say this may shed light on ... Black truffles (Tuber melanosporum), also known as Prigord truffles, ...
(Date:7/30/2014)... the Red Queen in Lewis Carroll,s Through the ... and National University of Singapore improved a 35-year-old ... over decades to millions of years. , The ... competition, incorporates the "Red Queen Effect," an evolutionary ... 1970s, which suggests that organisms must constantly increase ...
Breaking Biology News(10 mins):Engineering a protein to prevent brain damage from toxic agents 2How black truffles deal with the jumpers in their genome 2Classic Lewis Carroll character inspires new ecological model 2Classic Lewis Carroll character inspires new ecological model 3
Other Contents